[go: up one dir, main page]

DE602005011132D1 - Neuartige cis-imidazoline - Google Patents

Neuartige cis-imidazoline

Info

Publication number
DE602005011132D1
DE602005011132D1 DE602005011132T DE602005011132T DE602005011132D1 DE 602005011132 D1 DE602005011132 D1 DE 602005011132D1 DE 602005011132 T DE602005011132 T DE 602005011132T DE 602005011132 T DE602005011132 T DE 602005011132T DE 602005011132 D1 DE602005011132 D1 DE 602005011132D1
Authority
DE
Germany
Prior art keywords
novel cis
imidazoline
cis imidazoline
novel
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005011132T
Other languages
English (en)
Inventor
Nader Fotouhi
Gregory Jay Haley
Klaus B Simonsen
Binh Thanh Vu
Stephen Evan Webber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602005011132D1 publication Critical patent/DE602005011132D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26Radicals substituted by carbon atoms having three bonds to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005011132T 2004-05-18 2005-05-10 Neuartige cis-imidazoline Expired - Lifetime DE602005011132D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57227504P 2004-05-18 2004-05-18
US61553404P 2004-10-01 2004-10-01
US66877205P 2005-04-06 2005-04-06
PCT/EP2005/005046 WO2005110996A1 (en) 2004-05-18 2005-05-10 Novel cis-imidazolines

Publications (1)

Publication Number Publication Date
DE602005011132D1 true DE602005011132D1 (de) 2009-01-02

Family

ID=35058746

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005011132T Expired - Lifetime DE602005011132D1 (de) 2004-05-18 2005-05-10 Neuartige cis-imidazoline

Country Status (21)

Country Link
US (2) US7964724B2 (de)
EP (1) EP1753727B1 (de)
JP (1) JP4814228B2 (de)
KR (3) KR20080027969A (de)
CN (1) CN1953965B (de)
AR (1) AR049545A1 (de)
AT (1) ATE414693T1 (de)
AU (1) AU2005243465B2 (de)
BR (1) BRPI0511328A (de)
CA (1) CA2565189A1 (de)
DE (1) DE602005011132D1 (de)
ES (1) ES2314660T3 (de)
IL (1) IL178884A (de)
MX (1) MXPA06013246A (de)
MY (1) MY143800A (de)
NO (1) NO20065730L (de)
PE (1) PE20060679A1 (de)
RU (1) RU2006144811A (de)
TW (1) TW200600501A (de)
WO (1) WO2005110996A1 (de)
ZA (1) ZA200609595B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
US7579368B2 (en) * 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
ES2538714T3 (es) * 2005-12-01 2015-06-23 F. Hoffmann-La Roche Ag Derivados de 2,4,5-trifenil-imidazolina como inhibidores de la interacción entre las proteínas p53 y MDM2 para el uso en calidad de agentes anticancerosos
JP2009523751A (ja) * 2006-01-18 2009-06-25 エフ.ホフマン−ラ ロシュ アーゲー Mdm2阻害剤としてのシス−4,5−ビアリール−2−ヘテロサイクリック−イミダゾリン
JP2009542666A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション P53活性を増加させる置換ピペリジンおよびその使用
CN101541759A (zh) * 2006-11-27 2009-09-23 诺瓦提斯公司 取代的二氢咪唑类及其在治疗肿瘤中的用途
MX2009006397A (es) 2006-12-14 2009-08-13 Daiichi Sankyo Co Ltd Derivados de imidazotiazol.
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
EP2325180A1 (de) 2007-10-09 2011-05-25 F. Hoffmann-La Roche AG Chiral CIS-Imidazoline
EP2298778A4 (de) 2008-06-12 2011-10-05 Daiichi Sankyo Co Ltd Imidazothiazolderivat mit 4,7-diazaspiro[2.5]octan-ringstruktur
DE102008047128A1 (de) 2008-09-15 2010-04-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von cis-Imidazolinen, insbesondere Nutlinen, zur Behandlung von chemoresistenten Krebserkrankungen
CN102356085A (zh) 2009-01-16 2012-02-15 第一三共株式会社 具有脯氨酸环结构的咪唑并噻唑衍生物
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
AU2010319595B2 (en) 2009-11-12 2015-09-17 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
CA2813256A1 (en) 2010-09-30 2012-04-05 St. Jude Children's Research Hospital Aryl-substituted imidazoles
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールmdm2アンタゴニスト
CA2829188C (en) 2011-03-10 2016-10-18 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivatives
ES2624808T3 (es) 2011-05-11 2017-07-17 The Regents Of The University Of Michigan Antagonistas de MDM2 espirooxindólicos
EP2760845B1 (de) 2011-09-27 2016-11-16 Amgen Inc. Heterocyclische verbindungen als mdm2-hemmer zur behandlung von krebs
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
EP2771008A4 (de) 2011-10-28 2015-04-08 Merck Sharp & Dohme Makrozyklen zur erhöhung einer p53-aktivität und verwendungen davon
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG10201606775YA (en) 2012-02-15 2016-10-28 Aileron Therapeutics Inc Peptidomimetic macrocycles
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CA2887285A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲hdm2抑制劑之經取代咪唑吡啶
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2951180B1 (de) * 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (de) 2013-02-28 2017-09-27 Amgen Inc. Von der benzoesäure abgeleiteter mdm2-hemmer zur behandlung von krebs
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
EA029312B1 (ru) 2013-05-27 2018-03-30 Новартис Аг Производные имидазопирролидинона и их применение при лечении заболеваний
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PL3004108T3 (pl) 2013-05-28 2018-03-30 Novartis Ag Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
ES2650562T3 (es) 2013-05-28 2018-01-19 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades
CN104208066B (zh) * 2013-06-03 2016-06-15 中国科学院遗传与发育生物学研究所 哌嗪衍生物作为p53分子调节剂的用途
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN105916857B (zh) 2013-11-21 2018-06-22 诺华股份有限公司 吡咯并吡咯酮衍生物及其作为bet抑制剂的用途
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその使用
US10336698B2 (en) 2015-01-22 2019-07-02 Sanofi-Aventis Deutschland Gmbh Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその使用
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN109415336B (zh) 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック, インコーポレイテッド Protac抗体コンジュゲート及び使用方法
US20210198223A1 (en) * 2017-10-20 2021-07-01 Corbus Pharmaceuticals, Inc. Methods and compositions relating to ultrapure 5-(1,1-dimethylheptyl)-resorcinol
MX2021003999A (es) 2018-10-08 2021-06-23 Univ Michigan Regents Moleculas de bajo peso molecular degradadoras de la proteina mdm2.
US12528785B2 (en) 2020-03-19 2026-01-20 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11504381B1 (en) * 2021-11-22 2022-11-22 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
US11548866B1 (en) 2021-11-22 2023-01-10 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
KR102868976B1 (ko) 2021-12-10 2025-11-03 (주)잇마플 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
CN116903457A (zh) * 2023-07-18 2023-10-20 上海添泽生物医药有限公司 一种2-羟基-5-异丙基苯甲酸的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
DE4203547A1 (de) * 1992-02-07 1993-08-12 Knoll Ag Verfahren zur racemattrennung von verapamil
FR2756560A1 (fr) * 1996-12-04 1998-06-05 Adir Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
US6653501B2 (en) * 2001-06-27 2003-11-25 Napro Biotherapeutics, Inc. Chiral resolution method for producing compounds useful in the synthesis of taxanes
RU2305095C2 (ru) * 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
KR100640707B1 (ko) * 2001-12-18 2006-10-31 에프. 호프만-라 로슈 아게 Mdm2 저해제로서의 시스-이미다졸린

Also Published As

Publication number Publication date
CA2565189A1 (en) 2005-11-24
BRPI0511328A (pt) 2007-12-04
ZA200609595B (en) 2008-06-25
CN1953965A (zh) 2007-04-25
AR049545A1 (es) 2006-08-16
MY143800A (en) 2011-07-15
RU2006144811A (ru) 2008-06-27
JP4814228B2 (ja) 2011-11-16
AU2005243465A1 (en) 2005-11-24
WO2005110996A1 (en) 2005-11-24
KR100832277B1 (ko) 2008-05-26
ATE414693T1 (de) 2008-12-15
US20050288287A1 (en) 2005-12-29
IL178884A (en) 2010-12-30
KR20110033964A (ko) 2011-04-01
KR20080027969A (ko) 2008-03-28
EP1753727A1 (de) 2007-02-21
EP1753727B1 (de) 2008-11-19
NO20065730L (no) 2007-01-19
IL178884A0 (en) 2007-03-08
AU2005243465B2 (en) 2011-08-25
CN1953965B (zh) 2012-07-04
MXPA06013246A (es) 2007-02-08
KR20070011516A (ko) 2007-01-24
JP2007538022A (ja) 2007-12-27
US20090143364A1 (en) 2009-06-04
US7964724B2 (en) 2011-06-21
ES2314660T3 (es) 2009-03-16
PE20060679A1 (es) 2006-08-11
TW200600501A (en) 2006-01-01

Similar Documents

Publication Publication Date Title
DE602005011132D1 (de) Neuartige cis-imidazoline
CY2019034I1 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
DE112005001624A5 (de) Brillengestell
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
DE502005004843D1 (de) Einspritzventil
ATE459633T1 (de) Makrolide
DE502005004842D1 (de) Wischblatt
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE602005012491D1 (de) Zentrifugaldruckpumpe
DE502004012213D1 (de) Flachdichtung
DE602005027311D1 (de) Empfänger
DE202004017327U1 (de) Fitnessrad
DE502005002602D1 (de) Fahrzeugtemperiersystem
ATE521769T1 (de) Beschlag
DE502005004695D1 (de) Sicherheitsfangseil
AT500198B8 (de) Ladewagen
DE112005000794T5 (de) Urethanspritzpistolenanordnung
ATE389633T1 (de) Omega-phenyloctanamide
DE502005003159D1 (de) Kettenstichnähvorrichtung
DE502004001961D1 (de) Barikadenbrecher
AT500249A3 (de) Scheibenegge
DE502005004160D1 (de) Seitenblinkleuchte
DE112005002245A5 (de) Polymerdichtung
DE112005001019A5 (de) Kunststoffschraubverschlusskappe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition